Genetically modified tumor-targeted bacteria with reduced...

Details Genetically modified tumor-targeted bacteria with reduced... Genetically modified tumor-targeted bacteria with reduced...

2005-03-08

2005-03-08

Bui, Phuong T. (Department: 1638)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S258100, C424S093200, C424S093400, C435S252300, C435S252800, C435S879000

Reexamination Certificate

active

06863894

ABSTRACT:
The present invention is directed to mutantSalmonellasp. having a genetically modified msbB gene in which the mutantSalmonellais capable of targeting solid tumors. The invention is also directed toSalmonellasp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutantSalmonellafor growth inhibition and/or reduction in volume of solid tumors.

REFERENCES:
patent: 4436727 (1984-03-01), Ribi
patent: 5021234 (1991-06-01), Ehrenfeld
patent: 5344762 (1994-09-01), Karapetian
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 5997881 (1999-12-01), Powell et al.
patent: 6251406 (2001-06-01), Haefliger et al.
patent: 20010006642 (2001-07-01), Steidler et al.
patent: 98 94 6891 (1998-09-01), None
patent: WO 9106317 (1991-05-01), None
patent: WO 9211361 (1992-07-01), None
patent: WO 9502048 (1995-01-01), None
patent: WO 9611277 (1996-04-01), None
patent: WO 9634631 (1996-11-01), None
patent: WO 9640238 (1996-12-01), None
patent: WO 9718837 (1997-05-01), None
patent: WO 9719688 (1997-06-01), None
patent: WO 9725061 (1997-07-01), None
patent: WO 9833923 (1998-08-01), None
patent: WO 9840238 (1998-12-01), None
Adler, 1973, “A Method for Measuring Chemotaxis and Use of the Method to Determine Optimum Conditions for Chemotaxis byEscherichia coli”, J. Gen. Microbiol. 74:77-91.
Alizadeh et al., 1994, “Apoptosis as a Mechanism of Cytolysis of Tumor Cells by a Pathogenic Free-Living Amoeba”, Infect. Immun. 62:1298-1303.
Bagshawe, 1995, “Antibody-Directed Enzyme Prodrug Therapy: A Reiew”, Drug Dev. Res. 34:220-230.
Barry et al., 1995, “Protection Against Mycoplasma Infection Using Expression-Library Immunization”, Nature 377:632-635.
Barth and Morton, 1995, “The Role of Adjuvant Therapy in Melanoma Management”, Cancer 75 (Suppl.):726-734.
Berggren, 1995, “Recombinant Salmonella as an Oral HIV Vaccine”, NIH Project Number 5 K08 AI01248-02.
Bone, 1993, “Gram-Negative Sepsis: A Dilemma of Modern Medicine”, Clin. Microbiol. Rev. 6:57-68.
Bonnekoh et al., 1995, “Inhibition of Melanoma Growth by Adenoviral-Mediated HSV Thymidine Kinase Gene Transfer in vivo”, J. Invest. Derm. 104:313-317.
Carey et al., “Clostridial Oncolysis in Man”, Eur. J. Cancer 3:37-46.
Carrier et al., 1992, “Expression of Human IL-1β inSalmonella typhimurium;a Model System for the Delivery of Recombinant Therapeutic Proteins in vivo-”, J. Immunol. 148:1176-1181.
Carswell et al., 1975, “An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors”, Proc. Natl. Acad. Sci. USA 72:3666-3670.
Chabalgoity et al., 1996, “ASalmonella typhimurium htrALive Vaccine Expressing Multiple Copies of a Peptide Comprising Amino Acids 8-23 of Herpes Simplex Virus Glycoprotein D as a Genetic Fusion to Tetanus Toxin Fragment C Protects Mice from Herpes Simplex Virus Infection”, Mol. Microbiol. 19:791-801.
Christ et al., 1995, “E5531, A Pure Endotoxin Antagonist of High Potency”, Science 268:80-83. Clements, 1995, “Attenuated Salmonella as Vaccine Vectors”, NIH Project No. 5 R01 AI 28835-06.
Clementz et al., 1997, “Function of theEscherichia coli msbBGene, a Multicopy Suppressor of htrB Knockouts, in the Acylation of Lipid A”, J. Biol. Chem. 272(16):10353-10360.
Cunningham et al., 1992, “Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion”, Science 255:325-327.
Curtiss, 1995, “Biological Containment of Live Bacterial Vaccines”, NIH Project No. 1 R41 AI38599-01.
Curtiss, 1994, “Avirulent Salmonella Host-Vector Vaccine Systems,”, NIH Project No. 1 R41 AI36585-01.
Eisenstadt, 1987, “Analysis of Mutagenesis”, fromEscherichia coliandSalmonella typhimurium, Cellular and Molecular Biology,Neidhardt et al. (ed.), pp. 1016-1033.
Eisenstein et al., 1995, “Immunotherapy of a Plasmocytoma with Attenuated Salmonella”, Med. Oncol. 12:103-108.
Engelbart and Gericke, 1963, “Oncolysis by Clostridia. V. Transplanted Tumors of the Hamster”, Cancer Res. 24:239-243.
Falkow, 1991, “Bacterial Entry into Eukaryotic Cells”, Cell 65:1099-1102.
Fox et al., 1996, “Anaerobic Bacteria as a Delivery System for Cancer Gene Therapy: in vitro Activation of 5-Flurocytosine by Genetically Engineered Clostridia”, Gene Therapy 3:173-178.
Friberg, 1993, “BCG in the Treatment of Superficial Cancer of the Bladder: A Review”, Med. Oncol. Tumor Pharmacother. 10:31-36.
Galan, 1995, “Novel Salmonella Antigen Delivery Vectors”, NIH Project No. 5 R01 AI36520-02.
Gericke and Engelbart, 1963, “Oncolysis by Clostridia. II. Experiments on a Tumor Spectrum with a Variety of Clostridia in Combination with Heavy Metal”, Cancer Res. 24:217-221.
Gulig, 1994, “Salmonella typhimuriumVirulence Plasmid”, NIH Project No. 5 R29 AI28421-05.
Hall et al., 1994, “Induced Regression of Bovine Papillomas by Intralesional Immunotherapy”, Therapeutic Immunol. 1:319-324.
Han et al., 1967, “Salmonellosis in Disseminated Malignant Diseases”, New Eng. J. Med. 276:1045-1052.
Jain, 1994, “Barriers to Drug Delivery in Solid Tumors”, Sci. American 271:58-65.
Jones et al., 1992, “Invasion bySalmonella typhimuriumis Affected by the Direction of Flagellar Rotation”, Infect. Immun. 60:2475-2480.
Karow and Georgopoulos, 1992, “Isolation and Characterization of theEscherichia coli msbBGene, a Multicopy Suppressor of Null Mutations in the High-Temperature Requirement Gene htrB”, J. Bacteriol. 174:702-710.
Klimpel et al., 1990, “Bacteria-Infected Fibroblasts have Enhanced Susceptibility to the Cytotoxic Action of Tumor Necrosis Factor”, J. Immunol. 145:711-717.
Lee et al., 1992, “Identification of aSalmonella typhimuriumInvasion Locus by Selection for Hyperinvasive Mutants”, Proc. Natl. Acad. Sci. USA 89:1847-1851.
Lemmon et al., 1994, “Anaerobic Bacteria as a Gene Delivery System to Tumors”, Proc. Am. Assn. Cancer Res. 35:374 (Absract 2231).
Lemmon et al., 1997, “Anaerobic Bacteria as a Gene Delivery System that is Controlled by the Tumor Microenvironment”, Gene Therapy, 4:791-796.
Levine, 1995, “Recombinant and Live OralSalmonella typhiVaccines”, NIH Project No. 5 R01 AI29471-06.
Loppnow et al., 1990, “Cytokine Induction by Lipopolysaccharide (LPS) Corresponds to Lethal Toxicity and is Inhibited by NontoxicRhodobacter capsulatusLPS”, Infect. Immun. 58:3743-3750.
Lytvyn et al., 1992, “Comparison of the Thymidine Kinase Genes from Three Entomopoxviruses”, J. Gen. Virol. 73:3235-3240.
Macnab, 1992, “Genetics and Biogenesis of Bacterial Flagella”, Ann. Rev. Genet. 26:131-158.
Mahan et al., 1993, “Selection of Bacterial Virulence Genes that are Specifically Induced in Host Tissues”, Science 259:686-688.
McLaughlin et al., 1979, “Synergistic Activity of Components of Mycobacteria and Mutant Salmonella in Causing Regression of Line-10 Tumors in Guinea Pigs”, Cancer Res. 39:1766-1771.
Michalek, 1994, “Genetically Engineered Oral Vaccines and Caries Immunity”, Abstract, NIH Project no. 5 R01 DE09081-05.
Miller et al., 1989, “A Two-Component Regulatory System (phoP phoQ) ControlsSalmonella typhimuriumVirulence”, Proc. Natl. Acad. Sci. USA 86:5054-5058.
Miller, 1995, “Entry into Eukaryotic Cells by Salmonella and Yersinia”, NIH Project No. 5 K04 AI01230-02.
Miller et al., 1992, “An Unusual pagC::TnphoA Mutation Leads to an Invasion- an Virulence-Defective Phenotype in Salmonellae”, Infect. Immun. 60:3763-3770.
Minton et al., 1995, “Chemotherapeutic Tumor Targeting Using Clost

Affiliated with

Also associated with

Rating

Genetically modified tumor-targeted bacteria with reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genetically modified tumor-targeted bacteria with reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically modified tumor-targeted bacteria with reduced... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3437131